Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Al B. Benson, Alan Paul Venook, Mahmoud M. Al-Hawary et al. · Journal of the National Comprehensive Cancer Network · 2021
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section. These updates include recommendations for first-line use of checkpoint inhibitors for mCRC, that is deficient mismatch repair/microsatellite instability-high, recommendations related to the use of biosimilars, and expanded recommendations for biomarker testing. The systemic therapy recommendations now include targeted therapy options for patients with mCRC that is HER2-amplified, or BRAF V600E mutation-positive. Treatment and management of nonmetastatic or resectable/ablatable metastatic disease are discussed in the complete version of the NCCN Guidelines for Colon Cancer available at NCCN.org. Additional topics covered in the complete version include risk assessment, staging, pathology, posttreatment surveillance, and survivorship.
Cited by 1,696 works. doi:10.6004/jnccn.2021.0012
Authors
- Al B. Benson
- Alan Paul Venook
- Mahmoud M. Al-Hawary
- Mustafa A. Arain
- Yi‐Jen Chen
- Kristen Keon Ciombor
- Stacey A. Cohen
- Harry S. Cooper
- Dustin A. Deming
- Linda M. Farkas
- Ignacio Garrido‐Laguna
- Jean L. Grem
- Andrew John Gunn
- Joel Randolph Hecht
- Sarah E. Hoffe
- Joleen Marie Hubbard
- Steven R. Hunt
- Kimberly L. Johung
- Natalie N. Kirilcuk
- Smitha Krishnamurthi
References
- Mutations of the BRAF gene in human cancer
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
- Cancer statistics, 2020
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
- Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
- K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer